The latest verified Moderna-related update came on September 1, 2026, when Moderna announced upcoming investor-conference appearances. No Moderna events are currently scheduled over the next 48 hours.
Moderna’s most recent major business catalyst was the FDA’s approval of its updated 2026–2027 COVID-19 vaccines on August 27, 2026.
Because MRNAB is linked to Moderna stock, it may react to moves in MRNA. However, MRNAB’s comparatively lower liquidity can make short-term price action more volatile and less reflective of underlying fundamentals.
Moderna’s most recent major business catalyst was the FDA’s approval of its updated 2026–2027 COVID-19 vaccines on August 27, 2026.
Because MRNAB is linked to Moderna stock, it may react to moves in MRNA. However, MRNAB’s comparatively lower liquidity can make short-term price action more volatile and less reflective of underlying fundamentals.